SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix's upcoming earnings are sparking active debate, especially after the stock traded down in the after-hours session. While revenue was in line with estimates, EPS missed, and some community members are attributing the dip to a tax dispute in Brazil and broader concerns about content. A potential stock split and the impact of increased competition and advertising revenue are also key talking points.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as the stock experiences a significant pullback, prompting community discussion about potential bottom levels and future catalysts. Despite the recent downturn, some investors express confidence in the company's long-term prospects, citing a major deal with Microsoft and overall growth in the AI sector. Community members are actively debating whether to buy the dip or wait for further price declines.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending due to speculation around a potential acquisition, with community members weighing the possibility of a deal with Paramount Skydance or other interested parties like Netflix and Comcast. Discussions involve potential offer prices, the company's debt, and the strategic value of WBD's content library. The community is actively debating the likelihood of a buyout versus the company proceeding with its planned separation.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending due to anticipation surrounding its upcoming earnings report, with the community actively discussing potential outcomes and guidance. Bullish sentiment suggests the company will beat expectations, driven by strong global adoption of its da Vinci systems and procedure growth, despite concerns about tariffs and margin pressures. Traders are also closely monitoring unusual options activity and technical indicators for potential short-term opportunities.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to excitement around its Gemini APU, which a Cornell study showed matches GPU performance with significantly less energy consumption. The community is discussing potential partnerships, buyout scenarios, and the long-term implications for AI and data centers, while some are wary of a recent stock offering impacting the price. Overall, the focus is on GSIT's potential to disrupt the AI market with its energy-efficient technology.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending following its latest earnings report, with revenue exceeding expectations but EPS falling slightly short, leading to mixed sentiment. The community is actively discussing whether the results justify the stock's valuation amidst broader concerns about the macro environment and potential tariff impacts. Some believe TXN is undervalued and poised for a rally, while others are wary of the company's guidance and competitive landscape.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending due to a massive surge following news of a $200M financing deal aimed at advancing its schizophrenia treatment. Community chatter revolves around the potential for significant gains, while some traders caution about a possible pump and dump, leading to high volatility. The funding is viewed as a strong indicator of confidence in the drug's approval, sparking debates about its long-term potential versus short-term trading opportunities.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen ($SG) is trending as chatter suggests a potential short squeeze ahead of earnings, with community members noting high put/call ratios and significant options activity. Some investors believe the stock is oversold and undervalued, especially given its robotics technology from the SPYCE acquisition, while others are eyeing it as a sympathy play with other heavily shorted stocks like BYND making moves. Community members are actively discussing the potential for a gamma squeeze.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its acquisition of Railbird, a prediction market platform, sparking discussions about the company's expansion into new markets beyond sports betting. While some express excitement about this growth and potential, others are skeptical, citing concerns about profitability and regulatory challenges, with community members closely watching how this move impacts the stock's value.

rYojbaba Co., Ltd. engages in providing consulting and health services to improve and restore physical and mental health diminished by work-related stress. It operates through the Labor Consulting Services and Health Services segments. The Labor Consulting Services segment provides labor and corporate consulting services to foster constructive employment relationships between companies and employees. The Health Services segment provides health services through osteopathic clinics and osteopathic beauty salons to alleviate physical ailments primarily created by work related stress. The company was founded by Masataka Sakai on January 5, 2015 and is headquartered in Fukuoka, Japan.

rYojbaba Co. Ltd.

rYojbaba Co., Ltd. 

rYojbaba Co., Ltd. ($RYOJ) is trending due to a significant surge in price and volume, prompting discussions about potential short squeezes and comparisons to other recent high-momentum stocks. The community is actively speculating on targets and potential sympathy plays, with some noting the stock's low float and recent IPO status. News of partnerships may be contributing to market stimulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IO Biotech (IOBT) stock slumped 77% by Monday afternoon after the company announced that the U.S. Food and Drug Administration (FDA) recommended that the firm conduct another trial before submitting Cylembio for approval.IO Biotech held a meeting with the agency, which recommended that the firm not submit an application based on data from the IOB-013 clinical trial, in which Cylembio plus Merck’s Pembrolizumab improved progression-free survival (PFS), but narrowly missed statistical significance.“We look forward to continuing the dialogue with FDA to align on the design for a potential new registrational study. Additionally, we plan to discuss the data from our IOB-013 study with European regulators and determine a path to submission in the EU,” CEO Mai-Britt Zocca <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.iobiotech.com/news-events/news/news-details/2025/IO-Biotech-Provides-Update-Following-Pre-BLA-Meeting-with-FDA/default.aspx">said</a>.The company also stated that it is implementing a plan to conserve capital while seeking approval for the drug and conducting ongoing studies. IO Biotech currently has capital to sustain its operation into the first quarter of 2026. However, it is now planning restructuring, including a halving of its workforce.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IOBT">IOBT stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_2_10_50_PM_png_0d2cc62fff.webp" alt="IOBT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>IOBT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>Following the company’s announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target, as per TheFly. Given its cash position, the company would either need to raise additional capital, partner, or license out Cylembio to advance the new trial, the analyst noted.IO Biotech had <a href="https://stocktwits.com/news-articles/markets/equity/io-biotech-trial-of-cancer-therapy-plus-keytruda-misses-study-goal/chrHGKVRdeB">announced</a> in August that the late-stage trial of its investigational and therapeutic cancer vaccine, Cylembio, in combination with Pembrolizumab, failed to achieve statistical significance in terms of progression-free survival improvement compared to Keytruda alone.The trial evaluated Cylembio in combination with Keytruda versus Keytruda alone in 407 patients with previously untreated, unresectable, or metastatic (advanced) melanoma. Patients in the study treated with Cylembio in combination with Keytruda achieved a median progression-free survival of 19.4 months, compared to 11.0 months in patients treated with Keytruda alone. Progression-free survival (PFS) refers to the duration of time during and after cancer treatment during which a patient lives without the disease worsening.IOBT stock is down 61% this year and approximately 66% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/enanta-pharmaceuticals-stock-rises-despite-rsv-treatment-mid-stage-trial-failing-main-goal/chDuJaER3JS">Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine

Following the announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target. 

Equity

Following the announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target. 


IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know

IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with Merck’s (MRK) Keytruda, failed to achieve statistical significance in progression-free survival improvement in a late-stage trial compared to Keytruda alone.IOBT stock traded over 19% lower on Monday morning, at the time of writing. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://iobiotech.com/press-releases/?workflow=6562e614-30a0-4300-9a37-ab75253933a2">said</a> Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed. Improvement in progression-free survival was achieved across virtually all subgroups, including those with poor prognostic factors, the company said.The trial evaluated Cylembio in combination with Keytruda versus Keytruda alone in 407 patients with previously untreated, unresectable, or metastatic (advanced) melanoma. Patients in the study treated with Cylembio in combination with Keytruda achieved 19.4 months of median progression-free survival compared to 11.0 months in patients treated with Keytruda alone. Progression-free survival (PFS) refers to the length of time during and after cancer treatment that a patient lives without the disease worsening.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IOBT">IOBT</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_9_43_00_AM_png_243b1797b9.webp" alt="IOBT's Sentiment Meter and Message Volume as of 9:43 a.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>IOBT's Sentiment Meter and Message Volume as of 9:43 a.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the data.<stembedurl>https://stocktwits.com/Notnotshort/message/624573071</stembedurl>Another opined that the stock price should multiply by 10 times in the aftermath of the data release.<stembedurl>https://stocktwits.com/Abo_Hamza/message/624572510</stembedurl>A trend toward an improvement in overall survival was also observed in the study, though data is not yet mature, the company said. Overall survival (OS) is a key metric in clinical trials, particularly for cancer, representing the length of time from a specific event (like diagnosis or treatment start) that patients remain alive.“The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data,” said Mai-Britt Zocca, CEO of IO Biotech.IO Biotech plans to meet with the U.S. Food and Drug Administration (FDA) this fall to discuss the data and determine next steps for submission of a Biologics License Application (BLA) for the treatment of advanced melanoma.IOBT stock is up by 59% this year and by about 12% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/kroger-reaches-settlement-with-c-and-s-wholesale-grocers/chruzkSRdec">Big News On Kroger! Company Reaches Settlement With C&amp;S Wholesale Grocers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x

The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed.

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and IO Biotech (IOBT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN Research Report) and IO Biotech...

IO Biotech's Promising Phase 3 Cancer Vaccine Trial Advances

The latest announcement is out from IO Biotech (IOBT). On August 30, 2024, the Company revealed positive news from its Phase 3 trial of the cancer...

IO Biotech appoints Faical Miyara as CBO

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win...

IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Growth in Short Interest

IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 81,600 shares, a...

Comparing IO Biotech (NASDAQ:IOBT) and Evotec (OTCMKTS:EVTCY)

Evotec (OTCMKTS:EVTCY  Get Free Report) and IO Biotech (NASDAQ:IOBT  Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based...

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

IO Biotech Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.02
Prev Close	$0.8202
Open	$0.7921
Dividend Yield	0.00%
50-Day Moving Average	$1.33
Beta	0.81
Avg. Volume	3.15M
PE Ratio	-0.52

52-Week High	$2.79
52-Week Low	$0.3234
Market Capitalization	$54.04M
EPS (Annual)	-$1.45
Price to Book	33.95
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IOBT
IO Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IOBT News

IOBTIO Biotech Inc